Academic Journal
Combating multidrug-resistant pathogens, breast cancer (MCF-7) and hepatocellular carcinoma (HepG2) using biofabricated zinc oxide nanoparticles.
| Τίτλος: | Combating multidrug-resistant pathogens, breast cancer (MCF-7) and hepatocellular carcinoma (HepG2) using biofabricated zinc oxide nanoparticles. |
|---|---|
| Συγγραφείς: | El-Sherbiny GM; Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, 11884, Egypt. gamalelsherbiny1970@yahoo.com., Elkhashab DM; Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt., Shehata ME; Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, 11884, Egypt., Youssef ASE; Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. |
| Πηγή: | Scientific reports [Sci Rep] 2026 Aug 20; Vol. 16 (1). Date of Electronic Publication: 2026 Aug 20. |
| Τύπος έκδοσης: | Journal Article; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : Nature Publishing Group, copyright 2011- |
| Ιατρικοί όροι (MeSH): | Zinc Oxide*/chemistry , Zinc Oxide*/pharmacology , Breast Neoplasms*/drug therapy , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Drug Resistance, Multiple*/drug effects , Liver Neoplasms*/drug therapy , Metal Nanoparticles*/chemistry, Biofilms/drug effects ; Antioxidants/pharmacology ; Antioxidants/chemistry ; Drug Resistance, Neoplasm/drug effects ; Apoptosis/drug effects ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/chemistry ; Nanoparticles/chemistry ; Humans ; MCF-7 Cells ; Hep G2 Cells ; Microbial Sensitivity Tests ; Green Chemistry Technology ; Female |
| Περίληψη: | The escalating global burden of multidrug-resistant (MDR) infections and cancer necessitates the development of sustainable and multifunctional therapeutic strategies. Green-synthesized zinc oxide nanoparticles (ZnONPs) have emerged as promising nanomaterials owing to their unique physicochemical properties, broad-spectrum bioactivity, and environmentally friendly production routes. In this study, ZnONPs were biosynthesized using Citrus sinensis (orange) peel waste extract as a renewable reducing and stabilizing agent. The biosynthesized nanoparticles were comprehensively characterized by UV-Vis spectroscopy, FTIR, XRD, DLS, zeta potential analysis, SEM, TEM, HR-TEM, and SAED. Their antimicrobial, Time-kill kinetics, antibiofilm, antioxidant, and anticancer activities were systematically evaluated against clinically relevant MDR pathogens and human cancer cell lines. The biosynthesized ZnONPs exhibited an absorption peak at 368 nm, a mean hydrodynamic size of 32.45 nm, low polydispersity (0.186), and a zeta potential of - 36.4 mV, confirming excellent colloidal stability and highly crystalline hexagonal wurtzite nanostructures. ZnONPs demonstrated broad-spectrum antimicrobial activity, with MIC and MBC/MFC values ranging from 120 to 512 and 240 to 1024 µg/mL, respectively. Time-kill assays revealed concentration- and time-dependent antimicrobial effects, achieving complete microbial eradication at 4MIC within 8-12 h, while C. albicans remained the least susceptible species. Moreover, ZnONPs significantly inhibited microbial biofilm formation, with inhibition rates ranging from 55.2 to 68.3% at sub-MIC concentrations. Strong antioxidant activity was observed, with DPPH and ABTS radical-scavenging IC₅₀ values of approximately 38-40 μg/mL. Importantly, ZnONPs exhibited potent, dose-dependent, and selective anticancer activity against MCF-7 and HepG2 cells, with IC₅₀ values of 58.98 and 87.93 µg/mL, respectively, while showing minimal toxicity toward normal MCF-10A cells (IC₅₀ > 250 µg/mL; selectivity index > 4.24 for MCF-7 and > 2.84 for HepG2). Confocal microscopy demonstrated preferential and concentration-dependent nanoparticle uptake by cancer cells, which closely correlated with their enhanced cytotoxicity. Mechanistic studies further confirmed apoptosis induction through activation of the intrinsic mitochondrial pathway, as evidenced by significant upregulation of the pro-apoptotic gene BAX (3.4-fold in MCF-7 and 2.9-fold in MDA-MB-231 cells) and marked downregulation of the anti-apoptotic gene BCL2 (0.4-fold and 0.3-fold, respectively; p < 0.0001). Orange peel-mediated ZnONPs exhibit potent antimicrobial, antibiofilm, antioxidant, and selective anticancer activities, underscoring their potential as sustainable multifunctional nanotherapeutics for combating antimicrobial resistance and cancer. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Competing interests: The author(s) did not report any potential conflict of interest. Ethics approval and consent to participate: Clinical sample collection was performed only after obtaining written informed consent from all participating patients. The study protocol was reviewed and approved by the Institutional Review Board of the National Cancer Institute, Cairo University, Egypt (IRB No.: IRB-00004025; approval No.: CB2410-102-083-192), ensuring that all procedures complied with established ethical standards for biomedical research involving human participants. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. This correction has been made to avoid any ambiguity and ensure clarity regarding ethical approval and participant consent. |
| References: | Int J Biol Macromol. 2026 Apr;357:151510. (PMID: 41865933) Front Microbiol. 2023 Dec 04;14:1297528. (PMID: 38111644) Microb Pathog. 2018 Apr;117:128-138. (PMID: 29454824) JAC Antimicrob Resist. 2025 Sep 04;7(5):dlaf147. (PMID: 40917194) Cancer Lett. 2015 Oct 28;367(2):93-102. (PMID: 26170168) BMC Microbiol. 2024 Jul 9;24(1):254. (PMID: 38982372) RSC Adv. 2025 Oct 3;15(43):36534-36595. (PMID: 41048549) Chem Biol Interact. 2024 Nov 1;403:111245. (PMID: 39278458) Microb Pathog. 2022 Jan;162:105339. (PMID: 34861345) Sci Rep. 2025 May 22;15(1):17727. (PMID: 40399393) Molecules. 2023 Mar 07;28(6):. (PMID: 36985419) Nat Rev Microbiol. 2025 Feb;23(2):72-86. (PMID: 39251839) Eur J Clin Microbiol Infect Dis. 2025 Aug;44(8):1797-1816. (PMID: 40323347) Sci Data. 2019 Dec 5;6(1):307. (PMID: 31804487) Nanoscale Adv. 2024 Jul 1;6(16):4196-4206. (PMID: 39114140) Lancet. 2024 Sep 28;404(10459):1199-1226. (PMID: 39299261) Nat Rev Cancer. 2016 Feb;16(2):99-109. (PMID: 26822577) Life (Basel). 2022 Jun 15;12(6):. (PMID: 35743924) Lancet Reg Health Am. 2023 Aug 08;25:100561. (PMID: 37727594) Bioprocess Biosyst Eng. 2025 Jan;48(1):121-131. (PMID: 39503917) Artif Cells Nanomed Biotechnol. 2022 Dec;50(1):260-274. (PMID: 36191138) J Cell Sci. 2023 Nov 15;136(22):. (PMID: 37994778) Microb Pathog. 2024 Jul;192:106705. (PMID: 38761892) J Formos Med Assoc. 2021 Nov;120(11):1994-2002. (PMID: 33962811) Antioxidants (Basel). 2024 Dec 19;13(12):. (PMID: 39765890) Ann Med Surg (Lond). 2022 Nov 11;84:104882. (PMID: 36536737) Biochem Mosc Suppl B Biomed Chem. 2022;16(1):1-12. (PMID: 35194486) BMC Microbiol. 2025 Apr 23;25(1):235. (PMID: 40269700) Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59. (PMID: 18097445) J Antimicrob Chemother. 2024 Jul 1;79(7):1484-1492. (PMID: 38832539) Sci Rep. 2025 May 3;15(1):15477. (PMID: 40319186) Public Health Chall. 2026 Apr 15;5:e70229. (PMID: 41993053) Sci Rep. 2026 Feb 11;16(1):. (PMID: 41673180) Front Cell Infect Microbiol. 2026 Feb 19;16:1752304. (PMID: 41798743) Biomolecules. 2025 Feb 11;15(2):. (PMID: 40001569) Sci Rep. 2026 Feb 6;16(1):. (PMID: 41652097) J Antimicrob Chemother. 2020 May 1;75(5):1194-1205. (PMID: 32025716) ACS Appl Bio Mater. 2024 May 20;7(5):3014-3032. (PMID: 38597359) Oncotarget. 2015 Jan 30;6(3):1556-68. (PMID: 25596735) Clin Pharmacokinet. 2024 Nov;63(11):1609-1630. (PMID: 39476315) Trends Biotechnol. 2016 Jul;34(7):588-599. (PMID: 26944794) Ann N Y Acad Sci. 2015 Sep;1354:12-31. (PMID: 26190223) Biotechnol Notes. 2024 Feb 21;5:27-32. (PMID: 39416689) Nat Rev Cancer. 2002 Sep;2(9):647-56. (PMID: 12209154) Microbiol Res. 2023 Jan;266:127249. (PMID: 36356348) Food Chem Toxicol. 2016 Nov;97:286-296. (PMID: 27658325) Int J Infect Dis. 2025 Apr;153:107769. (PMID: 39725209) Sci Rep. 2024 Jan 25;14(1):2204. (PMID: 38273022) Biotechnol Rep (Amst). 2025 May 06;46:e00896. (PMID: 40487876) J Basic Microbiol. 2024 Jun;64(6):e2300614. (PMID: 38507723) J Biol Chem. 2017 Apr 21;292(16):6728-6743. (PMID: 28258218) J Control Release. 2016 Aug 10;235:337-351. (PMID: 27297779) World J Microbiol Biotechnol. 2025 Nov 27;41(12):476. (PMID: 41307779) BMC Microbiol. 2025 Oct 10;25(1):657. (PMID: 41073906) Nat Rev Mol Cell Biol. 2023 Oct;24(10):732-748. (PMID: 37438560) Adv Healthc Mater. 2026 May;15(20):e05091. (PMID: 41866811) Microb Pathog. 2026 Jul;216:108509. (PMID: 42025853) Environ Res. 2024 Jun 15;251(Pt 2):118770. (PMID: 38518913) Molecules. 2025 Feb 04;30(3):. (PMID: 39942788) Materials (Basel). 2020 Sep 23;13(19):. (PMID: 32977619) MedComm (2020). 2023 May 28;4(3):e288. (PMID: 37256211) NPJ Antimicrob Resist. 2023;1(1):5. (PMID: 38686214) Histochem Cell Biol. 2022 Sep;158(3):203-211. (PMID: 35829815) Commun Chem. 2025 Aug 25;8(1):258. (PMID: 40855189) |
| Contributed Indexing: | Keywords: Antibiofilm activity; Antioxidant activity; Apoptosis; Breast cancer; Green synthesis; Multidrug-resistant pathogens; Nanotherapeutics; Time–kill kinetics; ZnO nanoparticles |
| Substance Nomenclature: | SOI2LOH54Z (Zinc Oxide) 0 (Antineoplastic Agents) 0 (Antioxidants) 0 (Anti-Bacterial Agents) |
| Entry Date(s): | Date Created: 20260820 Date Completed: 20260821 Latest Revision: 20260823 |
| Update Code: | 20260823 |
| PubMed Central ID: | PMC13493932 |
| DOI: | 10.1038/s41598-026-66940-0 |
| PMID: | 42624907 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-026-66940-0 |